Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Cardiovasc. Med., 07 July 2025

Sec. Coronary Artery Disease

Volume 12 - 2025 | https://doi.org/10.3389/fcvm.2025.1650098

Correction: Podocan and adverse clinical outcome in patients admitted with suspected acute coronary syndromes

This article is a correction to:

  1. Podocan and Adverse Clinical Outcome in Patients Admitted With Suspected Acute Coronary Syndromes

    1. Read original article
Thomas Andersen, Thomas Andersen1,2*Thor Ueland,,Thor Ueland3,4,5Pl Aukrust,,Pål Aukrust3,4,6Dennis W. Nilsen,Dennis W. Nilsen7,8Heidi Grundt,Heidi Grundt8,9Harry StainesHarry Staines10Frederic Kontny, Frederic Kontny7,11
  • 1Department of Anesthesiology, Stavanger University Hospital, Stavanger, Norway
  • 2Department of Clinical Science (K2), University of Bergen, Bergen, Norway
  • 3Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
  • 4Institute of Clinical Medicine, University of Oslo, Oslo, Norway
  • 5K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, Tromsø, Norway
  • 6Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway
  • 7Department of Cardiology, Stavanger University Hospital, Stavanger, Norway
  • 8Department of Clinical Science, University of Bergen, Bergen, Norway
  • 9Department of Pulmonology, Stavanger University Hospital, Stavanger, Norway
  • 10Sigma Statistical Services, Balmullo, United Kingdom
  • 11Drammen Heart Center, Drammen, Norway

A Correction on

Podocan and adverse clinical outcome in patients admitted with suspected acute coronary syndromes

By Andersen T, Ueland T, Aukrust P, Nilsen DW, Grundt H, Staines H and Kontny F (2022). Front Cardiovasc Med. 9:867944. doi: 10.3389/fcvm.2022.867944

Affiliation “Department of Clinical Science (K2), University of Bergen, Bergen, Norway” was omitted from the paper. This affiliation has now been added for author Thomas Andersen.

The original version of this article has been updated.

Keywords: extracellular matrix, chest pain, acute coronary syndrome, risk factors, biomarkers, Podocan

Citation: Andersen T, Ueland T, Aukrust P, Nilsen DW, Grundt H, Staines H and Kontny F (2025) Correction: Podocan and adverse clinical outcome in patients admitted with suspected acute coronary syndromes. Front. Cardiovasc. Med. 12:1650098. doi: 10.3389/fcvm.2025.1650098

Received: 19 June 2025; Accepted: 26 June 2025;
Published: 7 July 2025.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright: © 2025 Andersen, Ueland, Aukrust, Nilsen, Grundt, Staines and Kontny. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Thomas Andersen, dGhvbWFzLmFuZGVyc2VuQHN1cy5ubw==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.